Disconnect between signalling potency and in vivo ef fi cacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

MOLECULAR METABOLISM

ELSEVIER

1. MRC
2. EFSD/Boehringer Ingelheim European Research Programme on Multi-System Challenges in Diabetes
3. BBSRC
4. NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award
5. EuroCHIP grant [FP7-HEALTH2009-241592]
6. NIHR Biomedical Research Centre Funding Scheme
7. Academy of Medical Sciences, Society for Endocrinology
8. EPSRC
9. Wellcome Trust [212625/Z/18/Z]
10. MRC Programme [MR/R022259/1]
11. Experimental Challenge Grant (DIVA) [MR/L02036X/1]
12. Diabetes UK [BDA/11/0004210, BDA/15/0005275, BDA 16/0005485]
13. EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking [115881]
14. MRC [MR/L02036X/1, MR/R010676/1, MR/R022259/1] Funding Source: UKRI